Bioverativ Therapeutics Inc. clinical trials
Acquired by Sanofi, Mar 8, 2018 · source ↗
The registry lists 12 studies whose lead sponsor is Bioverativ Therapeutics Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 8, 2021.
- 12studies on the registry
- 0open to participants now
Before and after it joined Sanofi
- First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- 12
- First submitted after Bioverativ Therapeutics Inc. became part of Sanofi
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Bioverativ Therapeutics Inc.’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- factor VIII-Fc fusion protein3 in phase 30 open · 5
- factor IX Fc fusion protein3 in phase 30 open · 4
- Factor IX1 in phase 30 open · 1
- Factor VIII1 in phase 30 open · 1
All 12 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 315
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Bioverativ Therapeutics Inc.12 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 12 of 12. All Sanofi studies →
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompletedNCT01181128Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Pharmacokinetics of rFVIIIFc at Two Vial StrengthsCompletedNCT02083965Phase 1
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell DiseaseCompletedNCT02447627
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia ACompletedNCT01454739Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompletedNCT00716716Phase 1
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompletedNCT01440946Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompletedNCT01458106Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BCompletedNCT01425723Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia BCompletedNCT01027364Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) ScaleCompletedNCT02502149Phase 3
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Fc factOrs and Real-World hemophiliA Patient-ReporteD OutcomesTerminatedNCT02392156
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi
- Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia ACompletedNCT01027377Phase 1
Sponsor listed in the registry: Bioverativ Therapeutics Inc. · First submitted before Bioverativ Therapeutics Inc. became part of Sanofi